Skip to main content

Advertisement

SpringerLink
Log in

The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy-1 antibody disulfide linked to the ribosome-inactivating protein gelonin

  • Original Articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

We prepared an immunoconjugate consisting of a monoclonal antibody recognizing the Thy-1 antigen and the ribosome-inactivating protein gelonin linked by a disulfide bond. This immunotoxin preparation was judged to contain less than 5% free antibody or gelonin. It was highly toxic in vitro in an antigen-specific fashion to the Thy-1 expressing RADA leukemia of A/J mice. The IC50 of this preparation on RADA in vitro was 10−12 M, while the IC50 on the Thy-1 negative S1509a fibrosarcoma of A/J mice was 10−7 M. The toxicity of this immunoconjugate was also measured in a direct proliferation assay and it was found that a 4-h exposure and a 24-h exposure of RADA cells to a 1 nM concentration of immunotoxin killed 90% and 99.9% of cells, respectively. Furthermore, efficacy in vitro was not due to the intrinsic susceptibility of RADA cells to tis type of immunotoxin, as one prepared with gelonin and an antibody recognizing the TLa determinant on this leukemia had no efficacy in vitro. Clearance of the anti-Thy-1-gelonin immunoconjugate from the circulation of A/J mice after i.v. injection was rapid, especially during the first 8 h after injection, possibly because of binding to Thy-1 expressing tissue. Delivery of immunoconjugate to ascitic tumor in vivo was substantially better if the immunoconjugate was given by i.p. injection, rather than by the i.v. route. When given either i.v. or i.p. at the time of i.p. tumor inoculation in vivo, the anti-Thy-1-gelonin immunotoxin showed potency in an antigen-specific fashion; while this immunoconjugate prolonged survival and frequently cured RADA-inoculated mice, neither anti-Thy-1 antibody, gelonin, a combination of the two, nor immunotoxin of irrelevant specificity had any significant effect on survival. Anti-Thy-1-gelonin also had no effect on survival of A/J mice inoculated i.p. with S1509a. Furthermore, it was determined that a single i.p. dose of anti-Thy-1-gelonin killed 90% to 99% cells in vivo, and that the immunoconjugate was about as effective in this model as either adriamycin or cytoxan.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Arnon R, Sela M (1982) In vitro and in vivo efficacy of conjugates of daunomycin with anti-tumor antibodies. Immunol Rev 62:5

    Google Scholar 

  2. Awdeh ZL, Williamson AR, Askonas BA (1970) One cell, one immunoglobulin. Biochem J 116:241

    Google Scholar 

  3. Badger CC, Bernstein ID (1983) Therapy of murine leukemia with a monoclonal antibody against a normal differentiation antigen. J Exp Med 157:828

    Google Scholar 

  4. Barbieri L, Stripe F (1982) Ribosome-inactivating proteins from plants; properties and possible uses. Cancer Surveys 1:489

    Google Scholar 

  5. Bernstein ID, Tam MR, Nowinski R (1980) Mouse leukemia: Therapy with monoclonal antibodies against a thymus differentiation antigen. Science 207:68

    Google Scholar 

  6. Bjorn MJ, Ring D, Frankel A (1985) Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins. Cancer Res 45:1214

    Google Scholar 

  7. Colombatti M, Bron C (1985) Sensitivity of target cells to immunotoxins: possible role of cell-surface antigens. Immunol Lett 55:331

    Google Scholar 

  8. Colombatti M, Nabholz M, Gros O, Bron C (1983) Selective killing target cells by antibody-Ricin A chain or antibody gelonin hybrid molecules: comparison of cytotoxic potency and use in immunoselection procedures. J Immunol 131:3091

    Google Scholar 

  9. Cowan NJ, Secher DS, Cotton RGH, Milstein C (1973) The secretion of a sialic acid-free immunoglobulin. FEBS Lett 30:343

    Google Scholar 

  10. Cox DR (1970) Analysis of binary data. Chapman and Hall, London

    Google Scholar 

  11. Cox DR, Oakes D (1984) Analysis of survival data. Chapman and Hall, London

    Google Scholar 

  12. Davignon D, Martz E, Reynolds T, Kurzinuciz K, Springer TA (1981) Lymphocyte function-associated antigen, (LFA-1); a surface antigen distinct from Lyt-2,3 that participates in Tlymphocyte mediated killing. Proc Natl Acad Sci USA 78:4535

    CAS  Google Scholar 

  13. Deweger RA, Dullens HFJ, Den Otter W (1982) Eradication of murine lymphoma and melanoma cells by chlorambucil antibody complexes. Immunol Rev 62:29

    Google Scholar 

  14. Diener E, Diver JE, Sinha A, Xie S, Vergidis R (1986) Specific immunosuppression by immunotoxins containing daunomycin. Science 231:148

    Google Scholar 

  15. Fraker PJ, Speck JC (1979) Protein and cell membrane iodinations with a sparingly soluble chloramide, 1,3,4,6-tetrachloro-3-alpha, 6 alpha-diphenylglycoluril. Biochem Biophys Res Commun 80:849

    Google Scholar 

  16. Fulton RJ, Blakey DC, Knowles PP, Uhr JW, Thorpe PE, Vitetta ES (1986) Purification of Ricin A1, A2, and B chains and characterization of their toxicity. J Biol Chem 261:5314

    Google Scholar 

  17. Further EF, Thilly WG, Penman BW, Liber HL, Rand WM (1981) Quantitative assay for mutation in diploid human lymphoblasts using microtiter plates. Anal Biochem 110:1–8

    Google Scholar 

  18. Giovanella BD, Fogh J (1982) Present and future trends with the nude mouse as a recipient of human tumor transplant. In: The nude mouse in experimental and clinical research vol 2. Academic Press

  19. Goldmacher VS, Anderson J, Blättler WA, Lambert JM, Senter PD (1985) Antibody-complement-mediated cytotoxicity is enhanced by ribosome-inactivating proteins. J Immunol 135:3648–3651

    Google Scholar 

  20. Goldmacher VS, Lambert JM, Yau-Young A, Anderson J, Tinnel NL, Kornacki M, Ritz J, Blättler W (1986) Expression of the common acute lymphoblastic leukemia antigen (CALLA) on the surface of individual cells of human lymphoblastoid lines. J Immunol 136:320

    Google Scholar 

  21. Greene MI, Perry LL, Benacerraf B (1979) Regulation of the immune response to tumor antigen. V. Modulation of suppressor T cell activity in vivo. Am J Pathol 95:159

    Google Scholar 

  22. Gunter KC, Kroczek RA, Shevach EM, Germain RN (1986) Functional expression of the murine Thy-1.2 gene in transfected human T cells. J Exp Med 163:285

    Google Scholar 

  23. Herlyn D, Koprowski H (1982) IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci USA 79:4761

    Google Scholar 

  24. Herlyn DM, Steplewki Z, Herlyn MF, Koprowski H (1980) Inhibition of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res 40:714

    Google Scholar 

  25. Houston LL, Nowinski LC (1981) Cell-specific cytotoxicity expressed by a conjugate of ricin and murine monoclonal antibody directed against the Thy1.1 antigen. Cancer Res 41:3913

    Google Scholar 

  26. Houston LL, Nowinski RC, Bernstein ID (1980) Specific in vivo localization of monoclonal antibodies directed against the Thy1.1 antigen. J Immunol 125:837

    Google Scholar 

  27. Hwang KM, Foon KA, Cheung DH, Pearson JW, Oldham RV (1984) Selective antitumor effect on L10 hepatocarcinoma cells of a potent immunoconjugate composed of the A chain of abrin and a monoclonal antibody to a hepatoma associated antigen. Cancer Res 44:4578

    Google Scholar 

  28. Jansen FK, Blythman HE, Carriere D, Casellas P, Gros O, Gros P, Laurent JG, Paolucci F, Pau B, Poncelet P, Richer G, Vidal H, Voisin G (1982) Immunotoxins: Hybrid molecules combining high specificity and potent cytotoxicity. Immunol Rev 62:185–216

    Google Scholar 

  29. Kaplan EL, Meier R (1958) Nonparametric estimation from incomplete observation. JASA 53:457–581

    Google Scholar 

  30. Kishida K, Masuho Y, Masahiki S, Hara T, Fuji A (1983) Ricin-A chain conjugated with monoclonal anti-L210 antibody. In vitro and in vivo anti-tumor activity. Cancer Immunol Immunother 16:93

    Google Scholar 

  31. Kroczek RA, Gunter KC, Seligmann B, Shevach EM (1986) Induction of T cell activation by monoclonal anti-Thy-1 antibodies. J Immunol 136:4379

    Google Scholar 

  32. Laemmli UK (1970) Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 227:681

    Google Scholar 

  33. Lambert JM, Senter PD, Yau-Young A, Blättler W, Goldmacher VS (1985) Purified immunotoxins that are reactive with human lymphoid cells. Monoclonal antibodies conjugated to the ribosome-inactivating proteins gelonin and the pokeweed anti-viral proteins. J Biol Chem 260:12035

    Google Scholar 

  34. Letvin NL, Goldmacher VS, Ritz J, Yetz JM, Schlossman SF, Lambert JM (1986) In vivo administration of lymphocyte-specific monoclonal antibodies in non-human primates: in vivo stability of disulfide-linked immunotoxin conjugates. J Clin Invest 77:977

    Google Scholar 

  35. MacDonald HR, Bron C, Rousseaux M, Horvotn M, Cerrottini JC (1985) Production and characterization of monoclonal anti-Thy-1 antibodies that stimulate lymphokine production by cytolytic T cell clones. Eur J Immunol 15:495

    Google Scholar 

  36. Masui H, Kawamoto T, Sato JD, Wolf B, Sato U, Mendelsohn J (1984) Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44:1002

    Google Scholar 

  37. Meuer SC, Hussey RE, Fabbi M, Fox D, Acuto O, Fitzgerald KA, Hodgdon JC, Reinherz EL (1984) An alternative pathway of T-cell activation: a functional role for the 50KD T11 sheep erythrocyte receptor protein. Cell 36:897

    Google Scholar 

  38. Moller G (ed) (1982) Antibody carriers of drugs and toxins in tumor therapy. Munksgaard International Publishers, Ltd, Immunol Rev 62

  39. Neville DM, Youle RJ (1982) Monoclonal antibody-Ricin or Ricin A chain hybrids: Kinetic analysis of cell killing for tumor therapy. Immunol Rev 62:75

    Google Scholar 

  40. Ohkawa V, Hibi N, Tsukada Y (1986) Evaluation of a conjugate of purified antibodies against human AFP-Dextran-daunomycin to human AFP-producing yolk sac tumor lines. Cancer Immunol Immunother 22:81

    Google Scholar 

  41. Pimm MV, Jones JA, Price MR, Middle JG, Embleton MJ, Baldwin RW (1982) Tumor localization of monoclonal antibody against a rat mammary carcinoma and suppression of tumor growth with conjugates. Cancer Immunol Immunother 12:125

    Google Scholar 

  42. Pirker R, Fitzgerald DJP, Hamilton TC, Ozols RF, Lard W, Frankel AE, Willingham MC, Pastan I (1985) Characterization of immunotoxins active against ovarian cancer cell lines. J Clin Invest 78:1761

    Google Scholar 

  43. Ramakrishnan S, Houston LL (1984) Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors, pokeweed antiviral protein or Ricin A chain. Cancer Res 44:1398

    Google Scholar 

  44. Raso V (1982) Antibody mediated delivery of toxic molecules to antigen-bearing target cells. Immunol Rev 62:93

    Google Scholar 

  45. Raso V, Ritz J, Basala M, Schlossman S (1982) Monoclonal antibody Ricin A chain conjugate selectively cytotoxic for cells bearing the common lymphoblastic leukemia antigen. Cancer Res 42:457

    Google Scholar 

  46. Rowland GF, Axton CA (1985) Antitumor properties of vindesine-monoclonal antibody conjugates. Cancer Immunol Immunother 19:1

    Google Scholar 

  47. Rowland GF, Simmonds RG, Gore JA, Marsden CH, Smith W (1986) Drug localization and growth inhibition studies of vindesin-monoclonal anti-CEA conjugates in a human tumor xenograft. Cancer Immunol Immunother 21:183

    Google Scholar 

  48. Schulz G, Staffileno LK, Reisfeld RA, Dennert G (1985) Eradication of established human melanoma tumors in nude mice by antibody directed target cells. J Exp Med 161:1315

    Google Scholar 

  49. Scott CF Jr, Lambert JM, Goldmacher VS, Blättler WA, Sobel R, Schlossman SF, Benacerraf B (1987) The pharmacokinetics and toxicity of murine monoclonal antibodies and of gelonin conjugates of these antibodies. Submitted for publication

  50. Seto M, Umemoto H, Saito M, Masuho Y, Hala T, Takahashi T (1982) Monoclonal anti-MM46 antibody: Ricin A chain conjugate in vitro and in vivo antitumor activity. Cancer Res 42:5201

    Google Scholar 

  51. Smyth MJ, Pietersz GA, Classon BJ, McKenzie IFC (1986) Specific targeting of chlorambucil to tumors with the use of monoclonal antibodies. J Natl Cancer Inst 76:503

    Google Scholar 

  52. Steplewski Z, Spira G, Blasczyk M, Lubeck MD, Radbruch A, Illges H, Herlyn D, Rajewsky V, Sharff M (1985) Isolation and characterization of anti-monosialoganglioside monoclonal antibody 19–9 class switch variants. Proc Natl Acad Sci USA 32:8653

    Google Scholar 

  53. Stripe F, Olsnes S, Phil A (1980) Gelonin, a new inhibitor of protein synthesis nontoxic to intact cells. J Biol Chem 74:6947

    Google Scholar 

  54. Thorpe PE, Ross WCJ (1982) The preparation and cytotoxic properties of antibody-toxin conjugates. Immunol Rev 62:119

    Google Scholar 

  55. Thorpe PE, Brown ANF, Ross WCJ, Cumber AJ, Dejle S, Edwards DC, Davies AJ, Stripe F (1981) Cytotoxicity acquired by conjugation of an anti-Thy1.1 monoclonal antibody and the ribosome inactivating protein gelonin. Eur J Biochem 116:447

    Google Scholar 

  56. Thorpe PE, Brown ANG, Bremmer JAG Jr, Foxwell BMJ, Stripe F (1985) An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosomal inactivating protein from Saponaria officinalis: Potent anti-tumor effects in vitro and in vivo. J Natl Cancer Inst 75:151

    Google Scholar 

  57. Trowbridge IS, Domingo DL (1981) Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumor cells. Nature 294:171

    Google Scholar 

  58. Vallera DA, Youle RJ, Neville DM, Kersey JH (1982) Bone marrow transplantation across major histocompatibility barriers. V. Protection of mice from lethal graft vs. host disease by pretreatment of donor cells with monoclonal anti-Thy-1.2 coupled to the toxin ricin. J Exp Med 155:949

    Google Scholar 

  59. Vitetta ES, Krolick KA, Uhr JW (1982) Neoplastic B cells as targets for antibody Ricin A chain immunotoxins. Immunol Rev 62:159

    Google Scholar 

  60. Vitetta ES, Krolick KA, Miyama-Inaba M, Cushley W, Uhr JW (1983) Immunotoxins: a new approach to cancer therapy. Science 122:644

    Google Scholar 

  61. Well-Hillman G, Ronge W, Jansen FV, Vallera DA (1985) Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model. Cancer Res 45:1328

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Tumor Immunology, Dana-Farber Cancer Institute, 44 Binney Street, 02 115, Boston, MA, USA

    Charles F. Scott Jr., Victor S. Goldmacher, John M. Lambert, Ravi V. J. Chari, Susan Bolender, Michael N. Gauthier & Walter A. Blättler

Authors
  1. Charles F. Scott Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Victor S. Goldmacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John M. Lambert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ravi V. J. Chari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Susan Bolender
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michael N. Gauthier
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Walter A. Blättler
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported by ImmunoGen Inc. and in part by a grant from the National Institutes of Health, CA-14723

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scott, C.F., Goldmacher, V.S., Lambert, J.M. et al. The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy-1 antibody disulfide linked to the ribosome-inactivating protein gelonin. Cancer Immunol Immunother 25, 31–40 (1987). https://doi.org/10.1007/BF00199298

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00199298

Keywords

Search

Navigation